Skip to main content
Fig. 5 | BMC Biotechnology

Fig. 5

From: Extracellular overproduction of E7 oncoprotein of Iranian human papillomavirus type 16 by genetically engineered Lactococcus lactis

Fig. 5

Kaplan–Meier plots of survival probability in C57BL/6-vaccinated mice (left panel) and TC-1 tumor-bearing C57BL/6 mice treated with recombinant strains (right panel); the data confirmed that immunization with L. lactis harboring pNZ8123-HPV16-optiE7 produced through fed-batch fermentation via the oral route generated the most powerful tumor protection (P < 0.0001). The survival time of tumor-bearing mice was considerably higher in the LLOE7FBF group. PBS (Control group); LLEV: Induced L. lactis harboring pNZ8123; LLE7BF: Induced L. lactis harboring pNZ8123-HPV16-E7 produced through batch fermentation; LLE7FBF: Induced L. lactis harboring pNZ8123-HPV16-E7 produced through fed-batch fermentation; LLOE7BF: Induced L. lactis harboring pNZ8123-HPV16-optiE7 produced through batch fermentation; and LLOE7FBF: Induced L. lactis harboring pNZ8123-HPV16-optiE7 produced through fed-batch fermentation

Back to article page
\